# Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

Source: https://onco.cc/trials/nct07033598/  
OnCo record `nct07033598` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pacritinib in chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Theradex, now recruiting.

## Summary

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia is a phase 2 interventional study registered as NCT07033598 by Theradex, with 66 participants planned, started 2026-01-01 and due to reach its primary completion in 2028-07. Interventions recorded: Pacritinib and Hydroxyurea.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07033598
- Phase: 2
- Setting: A Randomized Phase 2 Study of Pacritinib vs. Hydroxyurea in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia
- Sponsor: Theradex
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT07033598: https://clinicaltrials.gov/study/NCT07033598

## Connected records

- cancers: [Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms](https://onco.cc/cancers/cmml/)
- drugs: [Pacritinib](https://onco.cc/drugs/pacritinib/)
- companies: [Sobi (Swedish Orphan Biovitrum)](https://onco.cc/companies/sobi/)

---
JSON: https://onco.cc/api/v1/entities/nct07033598.json